ORKA

In the past six months, Oruka Therapeutics' stock has experienced notable movements, including being up more than 60% in the three months leading up to a news report. In April 2026, Oruka reported positive week 16 interim data from its EVERLAST-A trial for ORKA-001, which was a significant clinical proof-of-concept event. More recently, in September 2026, the stock was down 5% despite the announcement of positive Week 28 psoriasis efficacy data for ORKA-001 from the ongoing EVERLAST-A trial, showing deepening of responses without additional dosing. The company's stock also saw a 1-year change of +326.4% between October 3, 2025, and October 5, 2026, and a 1-month change of -8.8% between September 4, 2026, and October 5, 2026. The largest daily move recorded was a +25% close on March 13, 2026.